2023-12-01 14555059 2024-11-30 14555059 2023-12-01 2024-11-30 14555059 2023-11-30 14555059 2022-12-22 2023-11-30 14555059 uk-core:WithinOneYear 2023-11-30 14555059 uk-core:WithinOneYear 2024-11-30 14555059 uk-core:ShareCapital 2024-11-30 14555059 uk-core:ShareCapital 2023-11-30 14555059 uk-core:RetainedEarningsAccumulatedLosses 2024-11-30 14555059 uk-core:RetainedEarningsAccumulatedLosses 2023-11-30 14555059 uk-bus:Director1 2023-12-01 2024-11-30 iso4217:GBP xbrli:pure 14555059 uk-bus:AuditExemptWithAccountantsReport 2023-12-01 2024-11-30 14555059 uk-bus:FRS102 2023-12-01 2024-11-30 14555059 uk-bus:FilletedAccounts 2023-12-01 2024-11-30 14555059 uk-bus:PrivateLimitedCompanyLtd 2023-12-01 2024-11-30
ZY Pharma Limited
Registered Number:14555059
For the year ended 30 November 2024
England and Wales
Unaudited Financial Statements
2
For the year ended 30 November 2024
ZY Pharma Limited
Contents Page
1
Statement of Financial Position
2
Notes to the Financial Statements
3
Registered Number :
14555059
As at 30 November 2024
ZY Pharma Limited
Statement of Financial Position
£
£
2023
2024
Notes
Current assets
Trade and other receivables
6,436
8,166
2
35,140
Cash and cash equivalents
37,036
45,202
41,576
Trade and other payables: amounts falling due within one
year
(39,849)
(33,106)
3
1,727
12,096
Net current assets
Total assets less current liabilities
12,096
1,727
12,096
Net assets
1,727
Capital and reserves
Called up share capital
100
100
Retained earnings
11,996
1,627
12,096
1,727
Shareholders' funds
For the year ended 30 November 2024 the company was entitled to exemption from audit under Section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its financial statements for the year ended 30 November 2024 in accordance with Section 476 of the Companies Act 2006
The director acknowledges his responsibilities for:a) ensuring that the company keeps proper accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of
each financial year and of its profit or loss for each financial year in accordance with the requirements of Section
394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial
statements, so far as applicable to the company.
In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.
The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
Mohammed Mohasan Anwar Director
These financial statements were approved and authorised for issue by the Board on 24 August 2025 and were signed by:
The notes form part of these financial statements
1 of 2
4
For the year ended 30 November 2024
ZY Pharma Limited
Notes to the Financial Statements
Statutory Information
ZY Pharma Limited is a private limited company, limited by shares, domiciled in England and Wales, registration
number 14555059.
Registered address:
16 Meriton Road
Wilmslow
Cheshire
SK9 3HB
The presentation currency is £ sterling.
1. Accounting policies
Basis of preparing the financial statements
These financial statements have been prepared in accordance with the provisions of Section 1A of Financial
Reporting Standard 102 ''The Financial Reporting Standard applicable in the UK and Republic of Ireland'' and the
Companies Act 2006. The financial statements have been prepared under the historical costs convention as
modified by the revaluation of certain assets.
2. Trade and other receivables
2023
2024
£
£
Trade debtors
6,573
6,436
Other debtors
1,593
-
6,436
8,166
3. Trade and other payables: amounts falling due within one year
2023
2024
£
£
Taxation and social security
8,062
7,419
Other creditors
25,044
32,430
33,106
39,849
4. Average number of persons employed
During the year the average number of employees was 1 (2023 : 1)
2 of 2